Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its exec...
Catalent (CTLT) Up 4.1% Since Last Earnings Report: Can It Continue?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales
Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.
Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal...
Syringe Maker Catalent Anticipates Boost From Demand for Injectable Weight-Loss Drugs
Syringe maker Catalent (CTLT) said soaring demand for injectable weight-loss drugs could lead to big revenue gains, and shares surged over 11%.
Catalent, Inc. (CTLT) Q1 2024 Earnings Call Transcript
Catalent, Inc. (NYSE:CTLT ) Q1 2024 Earnings Call Transcript November 15, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President of Investor Relations John Greisch - Executive Chair of B...
Catalent doubles down on full year outlook as preliminary 1Q earnings beat estimates
Catalent shares added more than 11% after the contract drugmaker's preliminary first quarter earnings topped expectations and it reaffirmed its full-year fiscal 2024 guidance. For the quarter ended...
Catalent beats quarterly revenue estimates
Contract drug manufacturer Catalent on Wednesday beat Wall Street estimates for quarterly revenue as production showed signs of improvement on the back of a change in management.
Catalent Remains Overvalued
Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended...
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
Activist Elliott makes inroads at Catalent to build value. Here's what could happen next
Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company.
Catalent gets NYSE notice that it's not in compliance with listing rules over late 10-K filing
Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in compliance with listing rules due to a delay in fi...
Why Catalent Stock Zoomed 12% Higher This Week
The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings.
Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report
Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.
Why Catalent Stock Surged Nearly 5% Higher Today
The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts expected; guidance also topped expectations.
Related Companies